Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The company serves markets in the European Union, the United Kingdom, and the United States.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.